NEW IDEA ON MYRIAD GENETICS, THE INVENTOR OF BREAST CANCER GENETIC TEST $MYGN $LH $DGX
This post was just published on ZYX Short Change Alert. MYGN’s claim to fame is a test to identify BRCA mutations that increase the risk of breast and ovarian cancers. Previously, DGX announced plans to compete with MYGN. Today LH announced the nationwide availability of a suite of tests to identify
December 2, 2013